{"id":58225,"date":"2023-10-16T10:05:58","date_gmt":"2023-10-16T08:05:58","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/sotio-further-expands-next-generation-adc-platform-with-license-to-synaffixs-adc-technology\/"},"modified":"2023-10-16T10:05:58","modified_gmt":"2023-10-16T08:05:58","slug":"sotio-further-expands-next-generation-adc-platform-with-license-to-synaffixs-adc-technology","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/sotio-further-expands-next-generation-adc-platform-with-license-to-synaffixs-adc-technology\/","title":{"rendered":"SOTIO Further Expands Next-Generation ADC Platform with License to Synaffix\u2019s ADC Technology"},"content":{"rendered":"<div>\n<ul class=\"bwlistdisc\">\n<li>\n<b>SOTIO will leverage Synaffix\u2019s antibody-drug conjugate platform for the design of up to three novel ADCs to address indications with high unmet medical need<\/b><\/li>\n<li>\n<b>Collaboration bolsters SOTIO\u2019s wider portfolio of differentiated immuno-oncology therapies tailored to address the specific challenges of solid tumors<\/b><\/li>\n<li>\n<b>Synaffix will receive an upfront payment and potential development milestone payments totaling $740 million<\/b><\/li>\n<\/ul>\n<p>PRAGUE&#8211;(BUSINESS WIRE)&#8211;<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.sotio.com%2F&amp;esheet=53604119&amp;newsitemid=20231016342745&amp;lan=en-US&amp;anchor=SOTIO&amp;index=1&amp;md5=1fa9a4ef15401d4e7a8d80da8aa8576f\" rel=\"nofollow noopener\" shape=\"rect\"><b>SOTIO<\/b><\/a><b>, a clinical-stage immuno-oncology company owned by PPF Group, today announced a license and option agreement with Synaffix B.V., a Lonza company, to develop next-generation antibody-drug conjugates (ADCs) for the treatment of solid tumors. SOTIO will leverage Synaffix\u2019s ADC technology platform to develop up to three novel ADCs targeting distinct tumor-associated antigens.<\/b><\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20231016342745\/en\/1914804\/5\/sotio_logo.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20231016342745\/en\/1914804\/21\/sotio_logo.jpg\"><\/a><br \/><a href=\"https:\/\/mms.businesswire.com\/media\/20231016342745\/en\/1914804\/5\/sotio_logo.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20231016342745\/en\/1914804\/22\/sotio_logo.jpg\"><\/a><\/p>\n<p>\n\u201cAt SOTIO, we are building a broad pipeline of next-generation ADCs to address the challenges of solid tumors \u2013 and access to Synaffix\u2019s ADC platform technologies will ensure we remain at the leading edge of this space,\u201d said Radek Spisek, M.D., Ph.D., chief executive officer of SOTIO. \u201cThis collaboration combining SOTIO\u2019s deep expertise in solid tumor drug development with Synaffix\u2019s clinical-stage platform technology will drive important new innovations for the benefit of patients.\u201d<\/p>\n<p>\nThe deal enables SOTIO to combine its proprietary antibodies with Synaffix\u2019s ADC technology platform in order to deliver innovative new ADCs that can overcome the challenges of treating solid tumors. In addition to GlycoConnect\u2122 and HydraSpace\u2122, the deal also includes Synaffix\u2019s potent linker-payload platform including multiple different payloads.<\/p>\n<p>\n\u201cSynaffix\u2019s ADC technology perfectly complements the technologies already in SOTIO\u2019s ADC platform, including the iADC technology licensed from NBE-Therapeutics and the ConjuALL technology licensed from LegoChem,\u201d said Martin Steegmaier, chief scientific officer of SOTIO. \u201cThe addition of Synaffix\u2019s capabilities will greatly expand our ability to select and tailor the most suitable ADC technology and payload for the needs of a particular target and particular solid tumor indication.\u201d<\/p>\n<p>\nUnder the terms of the agreement, Synaffix is eligible to receive upfront and potential milestone payments worth up to $740 million, plus single-digit royalties on net sales. SOTIO will be responsible for research, development, manufacturing and commercialization of the ADC products, while Synaffix will closely support SOTIO\u2019s research activities and be responsible for the manufacturing of components that are specifically related to its proprietary GlycoConnect\u2122, HydraSpace\u2122, and linker-payload technologies.<\/p>\n<p>\nPeter van de Sande, head of Synaffix, added, \u201cThe selection of our ADC technologies by a seasoned ADC player like SOTIO is a strong recognition of the potential of these technologies to maximize the therapeutic index of ADCs. We look forward to partnering with SOTIO, and believe that with their singular focus on cancer immunotherapies and robust clinical pipeline, this partnership can deliver innovative medicines for patients in areas of high unmet medical need.\u201d<\/p>\n<p>\nSOTIO is advancing a pipeline of novel ADCs tailored to address the treatment needs of specific solid tumor types. SOT102, the company\u2019s most advanced ADC program, is a CLDN18.2-targeting ADC in Phase 1\/2 development for the treatment of gastric, pancreatic and other cancers that have very few targeted treatment options available. The company is progressing dose-finding studies in the trial\u2019s monotherapy arm, with SOT102 as a later-stage treatment, and recently announced the initiation of the trial\u2019s combination therapy arm in first-line treatment of gastric and pancreatic cancer patients. SOTIO additionally has two other ADC programs in preclinical development.<\/p>\n<p>\n<b>About Synaffix<\/b><\/p>\n<p>\nSynaffix B.V. is a biotechnology company that enables ADC product candidates using its clinical-stage, site-specific ADC technology platform based on GlycoConnect\u2122, HydraSpace\u2122 and toxSYN\u2122, that together enable any company with an antibody to develop proprietary best-in-class ADC products under a single license from Synaffix.<\/p>\n<p>\nThe Synaffix platform enables a rapid timeline to clinic due to the established supply chain of technology components. Granted patents covering Synaffix\u2019 technology provide end-to-end protection of the manufacturing technology as well as the resulting products through at least 2039. The business model of Synaffix is target-specific technology out-licensing, as exemplified through its existing deals with ADC Therapeutics, Mersana Therapeutics, Shanghai Miracogen (acquired by Lepu Biopharma), Innovent Biologics, ProfoundBio, Kyowa Kirin, Genmab, Macrogenics, Emergence Therapeutics (acquired by Eli Lilly), Amgen, Hummingbird Biosciences, Chong Kun Dang Pharma and ABL Bio.<\/p>\n<p>\nSynaffix was fully acquired by Lonza in June 2023. For more information, please visit the website at <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.synaffix.com&amp;esheet=53604119&amp;newsitemid=20231016342745&amp;lan=en-US&amp;anchor=www.synaffix.com&amp;index=2&amp;md5=2588ae6ef22c3b5e80e629313355bf00\" rel=\"nofollow noopener\" shape=\"rect\">www.synaffix.com<\/a>.<\/p>\n<p>\n<b>About SOTIO<\/b><\/p>\n<p>\nSOTIO Biotech (SOTIO) is shaping the future of cancer immunotherapies by translating compelling science into patient benefit. The SOTIO pipeline includes SOT102, a next-generation Claudin-18.2-targeted antibody-drug conjugate which entered the clinic in 2022; BOXR1030, a metabolically-enhanced CAR-T cell therapy targeting GPC3-expressing tumors as well as other molecules approaching clinical stage such as SOT201, our next-generation PD-1-inhibiting cytokine. SOTIO is a member of the PPF Group. For more information, please visit the company\u2019s website at <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sotio.com&amp;esheet=53604119&amp;newsitemid=20231016342745&amp;lan=en-US&amp;anchor=www.sotio.com&amp;index=3&amp;md5=dc642957587b15201b937b37a722bca8\" rel=\"nofollow noopener\" shape=\"rect\">www.sotio.com<\/a>.<\/p>\n<p>\nSOTIO is a registered trademark of SOTIO Biotech a.s. in selected countries.<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\n<b>Company contact:<br \/>\n<br \/>\n<\/b><br \/><b>Richard Kapsa<\/b><br \/><b>Head of Communication<\/b><br \/><b>T: <\/b>(+420) 224 174 448<br \/>\n<br \/><b>M:<\/b> (+420) 603 280 971<br \/>\n<br \/><a target=\"_blank\" href=\"&#109;&#x61;&#x69;l&#116;&#x6f;&#x3a;k&#97;&#x70;s&#97;&#x40;&#x73;o&#116;&#x69;o&#46;&#x63;&#x6f;m\" rel=\"nofollow noopener\" shape=\"rect\">&#x6b;a&#x70;&#115;a&#x40;&#115;&#x6f;&#x74;i&#x6f;&#46;c&#x6f;&#109;<\/a><\/p>\n<p>\n<b>Media contact:<br \/>\n<br \/>\n<\/b><br \/><b>Lisa Raffensperger<\/b><br \/><b>Ten Bridge Communications<\/b><br \/><b>M:<\/b> +1 (617) 903-8783<br \/>\n<br \/><a target=\"_blank\" href=\"&#109;&#x61;i&#108;&#x74;&#111;&#x3a;l&#105;&#x73;a&#x40;&#x74;&#101;&#x6e;b&#114;&#x69;d&#x67;&#x65;&#99;&#x6f;m&#109;&#x75;&#110;&#x69;c&#97;&#x74;i&#111;&#x6e;&#115;&#x2e;c&#111;&#x6d;\" rel=\"nofollow noopener\" shape=\"rect\">&#x6c;&#x69;&#115;&#97;&#64;&#x74;&#x65;&#x6e;&#98;&#114;i&#x64;&#x67;&#x65;&#99;&#111;m&#x6d;&#x75;&#x6e;&#105;&#99;a&#x74;&#x69;&#x6f;&#110;s&#46;&#x63;&#x6f;&#x6d;<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>SOTIO will leverage Synaffix\u2019s antibody-drug conjugate platform for the design of up to three novel ADCs to address indications with high unmet medical need Collaboration bolsters SOTIO\u2019s wider portfolio of differentiated immuno-oncology therapies tailored to address the specific challenges of solid tumors Synaffix will receive an upfront payment and potential development milestone payments totaling $740 &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/sotio-further-expands-next-generation-adc-platform-with-license-to-synaffixs-adc-technology\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-58225","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>SOTIO Further Expands Next-Generation ADC Platform with License to Synaffix\u2019s ADC Technology - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/sotio-further-expands-next-generation-adc-platform-with-license-to-synaffixs-adc-technology\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"SOTIO Further Expands Next-Generation ADC Platform with License to Synaffix\u2019s ADC Technology - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"SOTIO will leverage Synaffix\u2019s antibody-drug conjugate platform for the design of up to three novel ADCs to address indications with high unmet medical need Collaboration bolsters SOTIO\u2019s wider portfolio of differentiated immuno-oncology therapies tailored to address the specific challenges of solid tumors Synaffix will receive an upfront payment and potential development milestone payments totaling $740 ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/sotio-further-expands-next-generation-adc-platform-with-license-to-synaffixs-adc-technology\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-10-16T08:05:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20231016342745\/en\/1914804\/21\/sotio_logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sotio-further-expands-next-generation-adc-platform-with-license-to-synaffixs-adc-technology\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sotio-further-expands-next-generation-adc-platform-with-license-to-synaffixs-adc-technology\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"SOTIO Further Expands Next-Generation ADC Platform with License to Synaffix\u2019s ADC Technology\",\"datePublished\":\"2023-10-16T08:05:58+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sotio-further-expands-next-generation-adc-platform-with-license-to-synaffixs-adc-technology\\\/\"},\"wordCount\":843,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sotio-further-expands-next-generation-adc-platform-with-license-to-synaffixs-adc-technology\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20231016342745\\\/en\\\/1914804\\\/21\\\/sotio_logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sotio-further-expands-next-generation-adc-platform-with-license-to-synaffixs-adc-technology\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sotio-further-expands-next-generation-adc-platform-with-license-to-synaffixs-adc-technology\\\/\",\"name\":\"SOTIO Further Expands Next-Generation ADC Platform with License to Synaffix\u2019s ADC Technology - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sotio-further-expands-next-generation-adc-platform-with-license-to-synaffixs-adc-technology\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sotio-further-expands-next-generation-adc-platform-with-license-to-synaffixs-adc-technology\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20231016342745\\\/en\\\/1914804\\\/21\\\/sotio_logo.jpg\",\"datePublished\":\"2023-10-16T08:05:58+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sotio-further-expands-next-generation-adc-platform-with-license-to-synaffixs-adc-technology\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sotio-further-expands-next-generation-adc-platform-with-license-to-synaffixs-adc-technology\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sotio-further-expands-next-generation-adc-platform-with-license-to-synaffixs-adc-technology\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20231016342745\\\/en\\\/1914804\\\/21\\\/sotio_logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20231016342745\\\/en\\\/1914804\\\/21\\\/sotio_logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sotio-further-expands-next-generation-adc-platform-with-license-to-synaffixs-adc-technology\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"SOTIO Further Expands Next-Generation ADC Platform with License to Synaffix\u2019s ADC Technology\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"SOTIO Further Expands Next-Generation ADC Platform with License to Synaffix\u2019s ADC Technology - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/sotio-further-expands-next-generation-adc-platform-with-license-to-synaffixs-adc-technology\/","og_locale":"en_US","og_type":"article","og_title":"SOTIO Further Expands Next-Generation ADC Platform with License to Synaffix\u2019s ADC Technology - Pharma Trend","og_description":"SOTIO will leverage Synaffix\u2019s antibody-drug conjugate platform for the design of up to three novel ADCs to address indications with high unmet medical need Collaboration bolsters SOTIO\u2019s wider portfolio of differentiated immuno-oncology therapies tailored to address the specific challenges of solid tumors Synaffix will receive an upfront payment and potential development milestone payments totaling $740 ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/sotio-further-expands-next-generation-adc-platform-with-license-to-synaffixs-adc-technology\/","og_site_name":"Pharma Trend","article_published_time":"2023-10-16T08:05:58+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20231016342745\/en\/1914804\/21\/sotio_logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/sotio-further-expands-next-generation-adc-platform-with-license-to-synaffixs-adc-technology\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/sotio-further-expands-next-generation-adc-platform-with-license-to-synaffixs-adc-technology\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"SOTIO Further Expands Next-Generation ADC Platform with License to Synaffix\u2019s ADC Technology","datePublished":"2023-10-16T08:05:58+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/sotio-further-expands-next-generation-adc-platform-with-license-to-synaffixs-adc-technology\/"},"wordCount":843,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/sotio-further-expands-next-generation-adc-platform-with-license-to-synaffixs-adc-technology\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20231016342745\/en\/1914804\/21\/sotio_logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/sotio-further-expands-next-generation-adc-platform-with-license-to-synaffixs-adc-technology\/","url":"https:\/\/pharma-trend.com\/en\/sotio-further-expands-next-generation-adc-platform-with-license-to-synaffixs-adc-technology\/","name":"SOTIO Further Expands Next-Generation ADC Platform with License to Synaffix\u2019s ADC Technology - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/sotio-further-expands-next-generation-adc-platform-with-license-to-synaffixs-adc-technology\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/sotio-further-expands-next-generation-adc-platform-with-license-to-synaffixs-adc-technology\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20231016342745\/en\/1914804\/21\/sotio_logo.jpg","datePublished":"2023-10-16T08:05:58+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/sotio-further-expands-next-generation-adc-platform-with-license-to-synaffixs-adc-technology\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/sotio-further-expands-next-generation-adc-platform-with-license-to-synaffixs-adc-technology\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/sotio-further-expands-next-generation-adc-platform-with-license-to-synaffixs-adc-technology\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20231016342745\/en\/1914804\/21\/sotio_logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20231016342745\/en\/1914804\/21\/sotio_logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/sotio-further-expands-next-generation-adc-platform-with-license-to-synaffixs-adc-technology\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"SOTIO Further Expands Next-Generation ADC Platform with License to Synaffix\u2019s ADC Technology"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/58225","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=58225"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/58225\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=58225"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=58225"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=58225"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}